{
    "8XB.F": {
        "short_name": "BIOCARTIS GR. 144A/REG S",
        "long_name": "Biocartis Group NV",
        "summary": "Biocartis Group NV, a molecular diagnostics company, provides diagnostic solutions enhancing clinical practice for the benefit of patients, clinicians, payers, and healthcare industry with a focus on oncology. Its proprietary molecular diagnostics Idylla platform is a real-time polymerase chain reaction system that offers molecular information that allows treatment selection and treatment progress monitoring. The company offers formalin fixed, paraffin embedded solid biopsy tests, including diagnostic products, such as Idylla BRAF, KRAS, NRAS-BRAF, NRAS, and EGFR mutation tests; and research products, which include Idylla MSI and NRAS-BRAF-EGFR S492R mutation assays. It also provides plasma liquid biopsy tests comprising diagnostic products that include Idylla ctKRAS and ctNRAS-BRAF mutation tests; and research products consisting of Idylla ctBRAF and ctNRAS-BRAF-EGFR S492R mutation assays. The company has a collaboration agreement with AstraZeneca to develop and commercialize Idylla based molecular tests in support of AstraZeneca's pharmaceutical products; Bristol-Myers Squibb Company for the registration of Idylla MSI Test as companion diagnostic test for metastatic colorectal cancer in China; and Endpoint Health, Inc. for the development and commercialization of a novel companion diagnostic test based on Idylla molecular diagnostics platform. Biocartis Group NV was founded in 2007 and is headquartered in Mechelen, Belgium.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "Belgium",
        "city": "Mechelen"
    },
    "BCART.BR": {
        "short_name": "BIOCARTIS",
        "long_name": "Biocartis Group NV",
        "summary": "Biocartis Group NV, a molecular diagnostics company, provides diagnostic solutions enhancing clinical practice for the benefit of patients, clinicians, payers, and healthcare industry with a focus on oncology. Its proprietary molecular diagnostics Idylla platform is a real-time polymerase chain reaction system that offers molecular information that allows treatment selection and treatment progress monitoring. The company offers formalin fixed, paraffin embedded solid biopsy tests, including diagnostic products, such as Idylla BRAF, KRAS, NRAS-BRAF, NRAS, and EGFR mutation tests; and research products, which include Idylla MSI and NRAS-BRAF-EGFR S492R mutation assays. It also provides plasma liquid biopsy tests comprising diagnostic products that include Idylla ctKRAS and ctNRAS-BRAF mutation tests; and research products consisting of Idylla ctBRAF and ctNRAS-BRAF-EGFR S492R mutation assays. The company has a collaboration agreement with AstraZeneca to develop and commercialize Idylla based molecular tests in support of AstraZeneca's pharmaceutical products; Bristol-Myers Squibb Company for the registration of Idylla MSI Test as companion diagnostic test for metastatic colorectal cancer in China; and Endpoint Health, Inc. for the development and commercialization of a novel companion diagnostic test based on Idylla molecular diagnostics platform. Biocartis Group NV was founded in 2007 and is headquartered in Mechelen, Belgium.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "BRU",
        "market": "be_market",
        "country": "Belgium",
        "city": "Mechelen"
    },
    "MDXH.BR": {
        "short_name": "MDXHEALTH",
        "long_name": "MDxHealth SA",
        "summary": "MDxHealth SA operates as a molecular diagnostics company in Germany, the Netherlands, Belgium, Spain, Poland, Italy, the United States, rest of European Union, and internationally. The company develops and commercializes epigenetic and other molecular tests for cancer assessment and the personalized treatment of patients. Its tests are based on genetic, epigenetic, and other molecular technologies, as well as assist physicians with the diagnosis of urologic cancers, prognosis of recurrence risk, and prediction of response to a specific therapy. The company's product pipeline includes tests for bladder, kidney, and other urologic cancers. Its products include ConfirmMDx, a tissue test for prostate cancer; SelectMDx, a non-invasive urine test for prostate cancer; and AssureMDx. The company was formerly known as OncoMethylome Sciences SA and changed its name to MDxHealth SA in October 2010. MDxHealth SA was founded in 2003 and is headquartered in Herstal, Belgium.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "BRU",
        "market": "be_market",
        "country": "Belgium",
        "city": "Herstal"
    },
    "MXDHF": {
        "short_name": "MDXHEALTH",
        "long_name": "MDxHealth SA",
        "summary": "MDxHealth SA operates as a molecular diagnostics company in Germany, the Netherlands, Belgium, Spain, Poland, Italy, the United States, rest of European Union, and internationally. The company develops and commercializes epigenetic and other molecular tests for cancer assessment and the personalized treatment of patients. Its tests are based on genetic, epigenetic, and other molecular technologies, as well as assist physicians with the diagnosis of urologic cancers, prognosis of recurrence risk, and prediction of response to a specific therapy. The company's product pipeline includes tests for bladder, kidney, and other urologic cancers. Its products include ConfirmMDx, a tissue test for prostate cancer; SelectMDx, a non-invasive urine test for prostate cancer; and AssureMDx. The company was formerly known as OncoMethylome Sciences SA and changed its name to MDxHealth SA in October 2010. MDxHealth SA was founded in 2003 and is headquartered in Herstal, Belgium.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "PNK",
        "market": "us_market",
        "country": "Belgium",
        "city": "Herstal"
    },
    "O6C.F": {
        "short_name": "MDXHEALTH S.A.",
        "long_name": "MDxHealth SA",
        "summary": "MDxHealth SA operates as a molecular diagnostics company in Germany, the Netherlands, Belgium, Spain, Poland, Italy, the United States, rest of European Union, and internationally. The company develops and commercializes epigenetic and other molecular tests for cancer assessment and the personalized treatment of patients. Its tests are based on genetic, epigenetic, and other molecular technologies, as well as assist physicians with the diagnosis of urologic cancers, prognosis of recurrence risk, and prediction of response to a specific therapy. The company's product pipeline includes tests for bladder, kidney, and other urologic cancers. Its products include ConfirmMDx, a tissue test for prostate cancer; SelectMDx, a non-invasive urine test for prostate cancer; and AssureMDx. The company was formerly known as OncoMethylome Sciences SA and changed its name to MDxHealth SA in October 2010. MDxHealth SA was founded in 2003 and is headquartered in Herstal, Belgium.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "Belgium",
        "city": "Herstal"
    }
}